Research dossier
Cagrilintide — amylin analogue dossier
An amylin analogue designed for an extended half-life, studied alongside the incretin agonists.
Translated from the French original, which remains the reference version: lire en français →
Molecular identity
| Parameter | Value |
|---|---|
| CAS number | 1415456-99-3 |
| Molar mass | 4409.0 g/mol |
| Molecular formula | C₁₉₄H₃₁₂N₅₄O₅₉S₂ |
| Sequence / nature | Analogue de l’amyline à action prolongée |
| Purity | ≥99% |
| Appearance | White lyophilised powder |
The values above correspond to the catalogue lot and are reproduced as they stand from the product page. Any discrepancy between this dossier and the product page should be reported before use.
Research context
Amylin was long difficult to study because of its instability in solution. Stabilised analogues reopened the field by making reproducible prolonged exposures possible. The available literature remains young, and characterising the AMY receptor subtypes is still an active methodological undertaking — RAMP co-expression being technically demanding.
Mechanism studied
Cagrilintide is a synthetic analogue of amylin, a 37 amino acid peptide hormone co-secreted with insulin by the pancreatic beta cells. Native amylin is described as unstable in solution, with a strong propensity to aggregate into fibrils; the sequence modifications carried by cagrilintide are aimed precisely at limiting that aggregation and extending the plasma half-life.
The amylin receptors are not independent entities: the literature describes them as complexes formed by the calcitonin receptor associated with a RAMP (receptor activity-modifying protein). The RAMP1, RAMP2 and RAMP3 combinations define the AMY1, AMY2 and AMY3 subtypes respectively, whose pharmacological profiles differ.
That composite architecture explains why in-vitro assays on this compound require controlled co-expression systems: a calcitonin receptor expressed alone does not reproduce amylin pharmacology.
In-vitro literature
The available publications concern characterisation of affinity at the different AMY subtypes, aggregation kinetics compared with native amylin, and cAMP signalling measurements in recombinant cell lines. Conformational stability in solution is a recurring methodological parameter in that work.
Bibliographic entry points
- PubMed — peer-reviewed literature
- PubChem — chemical profile and assay data
- NCBI — methodology and receptor references
These links are an entry point into the literature, not an edited selection. None of the sources cited relates to a human use of this material, and consulting them directly is recommended for any protocol design.
Distinguishing this compound from its analogues
Distinct from native amylin (pramlintide included) in sequence and kinetics. Since the AMY receptors require RAMP co-expression, data obtained on the calcitonin receptor alone are not transferable.
The CAS number shown on the product page is the identifier to rely on. Trade names, development codes and customary abbreviations vary from one source to another and are not a reliable identification.
Methodological limits
The aggregation propensity of the amylin family is the principal experimental limit. A solution that has begun to form oligomers no longer holds the same concentration of active monomer, without that necessarily being visible. A check by dynamic light scattering or thioflavin T is advisable for any prolonged exposure protocol.
These limits are not formalities: they determine what a protocol using this material can and cannot establish. Making them explicit in the experimental plan avoids attributing to the compound an observation that belongs to the measurement system.
Analytical parameters
The aggregation tendency characteristic of this family requires particular attention to the reconstitution protocol and to storage of the solution. Purity analyses are carried out on the lyophilised material, before it is put into solution.
| Parameter | Value |
|---|---|
| Storage | Store at −20 °C, protected from light |
| Solubility | Soluble in bacteriostatic water (BAC) |
| Stability | Stable for 24 months at −20 °C; 30 days after reconstitution at 2–8 °C |
| Control methods | RP-HPLC · MS · NMR |
Reconstitution is a matter for the experimental protocol. The volume of solvent determines the final concentration and is not prescribed here: it depends on the design of the experiment and the conditions of the assay.
Resulting concentrations
The table below is arithmetic: it gives the concentration obtained for a given solvent volume, with no recommendation of use.
| Format | 1 ml | 2 ml | 3 ml |
|---|---|---|---|
| 10mg | 10.00 mg/ml | 5.00 mg/ml | 3.33 mg/ml |
These values assume complete dissolution and a peptide content consistent with the lot report. Where the actual quantitative content differs from the nominal mass — a common discrepancy, caused by counter-ions and residual water — the effective concentration is lower than the theoretical value. That is precisely why quantitative content per vial forms part of the verification protocol.
Protocol design
Three points govern the validity of an assay using this material, whatever the question being asked.
The effective concentration is not the nominal concentration. It depends on the actual peptide content of the lot, on complete dissolution and on adsorption to the walls of the container. A concentration check after reconstitution is preferable to assuming a perfect yield.
The actual exposure time may be shorter than the nominal duration where the compound is degraded by the medium. Verify stability under the exact conditions of the assay — medium, serum, temperature, duration — before interpreting an absence of effect.
The control arm must correspond to the vehicle actually used, at the same final concentration. This requirement is unremarkable and remains the most frequent cause of irreproducible results.
Lot verification
The following formats are covered by a Janoshik Analytical report, readable from the product page:
- 10mg — lot report available
| Format | Lot report | Availability |
|---|---|---|
| 10mg | Covered | In stock |
The verification programme covers exclusively the identity and purity of the material, by reversed-phase chromatography and mass spectrometry. It covers neither sterility, nor endotoxins, nor any microbiological characteristic.
Frequently asked questions
How does this product arrive?
As a lyophilised powder in a sealed vial, shipped in insulated, plain packaging. Return the vial to the storage temperature given in the specifications on receipt.
Which solvent should be used for reconstitution?
Bacteriostatic water is the usual reconstitution solvent for lyophilised peptides in a laboratory setting. The volume is a matter for the experimental protocol and the concentration sought; we provide no dosage recommendation.
How long does the material remain stable?
The stability window appears in the specifications table on this page, before and after reconstitution. Those values correspond to the storage conditions stated; any temperature variation shortens them.
Does the analysis report correspond exactly to my vial?
The report linked on this page corresponds to the format selected. Each report is issued by Janoshik Analytical from an anonymously submitted sample, and covers the identity and purity of the peptide.
Can this product be used on humans or animals?
No. It is an analytical grade reference material intended exclusively for in-vitro laboratory research. Any administration to humans or animals is excluded, and no therapeutic, diagnostic or medical claim is made.
Dossiers in the same category
- Retatrutide — CAS 2381089-83-2